Cargando…
The treatment of mitral insufficiency in refractory heart failure
Secondary mitral insufficiency (SMI) is caused by dilatation and left ventricular dysfunction and is a frequent finding in patients with heart failure (HF). It is associated with a mortality of between 40% and 50% at 3 years. The first-line treatment is represented by medical therapy, possibly assoc...
Autores principales: | Cammertoni, Federico, Bruno, Piergiorgio, Mazza, Andrea, Massetti, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904083/ https://www.ncbi.nlm.nih.gov/pubmed/33654472 http://dx.doi.org/10.1093/eurheartj/suaa143 |
Ejemplares similares
-
Implantable ventricular assistance systems (VAD) as a bridge to transplant or as ‘destination therapy’
por: Nesta, Marialisa, et al.
Publicado: (2021) -
Delayed massive subcutaneous emphysema following Robicsek closure
por: Pavone, Natalia, et al.
Publicado: (2019) -
Unexpected diagnosis following screening breast ultrasound
por: Cammertoni, Federico, et al.
Publicado: (2020) -
Usability, performance and safety of a new device for degenerative mitral regurgitation: in vivo chronic evaluation
por: Zeitani, Jacob, et al.
Publicado: (2022) -
Canine Pancreatic‐Specific Lipase Concentrations in Dogs with Heart Failure and Chronic Mitral Valvular Insufficiency
por: Han, D., et al.
Publicado: (2015)